Advertisement

PharmacoEconomics

, Volume 27, Issue 7, pp 533–545 | Cite as

Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines

  • Natasha K. StoutEmail author
  • Amy B. Knudsen
  • Chung Yin Kong
  • Pamela M. McMahon
  • G. Scott Gazelle
Review Article

Abstract

Increasingly, computer simulation models are used for economic and policy evaluation in cancer prevention and control. A model’s predictions of key outcomes, such as screening effectiveness, depend on the values of unobservable natural history parameters. Calibration is the process of determining the values of unobservable parameters by constraining model output to replicate observed data. Because there are many approaches for model calibration and little consensus on best practices, we surveyed the literature to catalogue the use and reporting of these methods in cancer simulation models.

We conducted a MEDLINE search (1980 through 2006) for articles on cancer-screening models and supplemented search results with articles from our personal reference databases. For each article, two authors independently abstracted pre-determined items using a standard form. Data items included cancer site, model type, methods used for determination of unobservable parameter values and description of any calibration protocol. All authors reached consensus on items of disagreement. Reviews and non-cancer models were excluded. Articles describing analytical models, which estimate parameters with statistical approaches (e.g. maximum likelihood) were catalogued separately.Models that included unobservable parameters were analysed and classified by whether calibration methods were reported and if so, the methods used.

The review process yielded 154 articles that met our inclusion criteria and, of these, we concluded that 131 may have used calibration methods to determine model parameters. Although the term ‘calibration’ was not always used, descriptions of calibration or ‘model fitting’ were found in 50% (n = 66) of the articles, with an additional 16% (n = 21) providing a reference to methods. Calibration target data were identified in nearly all of these articles. Other methodological details, such as the goodness-of-fit metric, were discussed in 54% (n = 47 of 87) of the articles reporting calibration methods, while few details were provided on the algorithms used to search the parameter space.

Our review shows that the use of cancer simulation modelling is increasing, although thorough descriptions of calibration procedures are rare in the published literature for these models. Calibration is a key component of model development and is central to the validity and credibility of subsequent analyses and inferences drawn from model predictions. To aid peer-review and facilitate discussion of modelling methods, we propose a standardized Calibration Reporting Checklist for model documentation.

Keywords

Calibration Method Comparative Effectiveness Research Calibration Target Calibration Protocol Unobservable Parameter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors gratefully acknowledge the support of Drs Eric Feuer and Karen Kuntz and members of the NCI Cancer Intervention and Surveillance Modeling Network. This work was supported in part by grants from the National Cancer Institute: F32 CA125984 (Natasha K. Stout), R25 CA92203 (Amy B. Knudsen), K99 126147 (Pamela M. McMahon, Chung Yin Kong) and R01 97337 (G. Scott Gazelle, Pamela M. McMahon, Chung Yin Kong). The funding agreements ensured the authors’ independence in designing the study, collecting, analysing and interpreting the data and writing and publishing the report. An earlier version of this work was presented at the 2007 Society for Medical Decision Making Annual Meeting.

Supplementary material

40273_2012_27070533_MOESM1_ESM.pdf (129 kb)
Supplementary material, approximately 132 KB.

References

  1. 1.
    Ramsey SD, McIntosh M, Etzioni RD, et al. Simulation modeling of outcomes and cost-effectiveness. Hematol Oncol Clin North Am 2000 Aug; 14 (4): 925–38PubMedCrossRefGoogle Scholar
  2. 2.
    Knudsen AB, McMahon PM, Gazelle GS. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol 2007; 25: 203–8PubMedCrossRefGoogle Scholar
  3. 3.
    Feuer EJ, Etzioni RD, Cronin KA, et al. The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing. Stat Methods Med Res 2004 Dec; 13: 421–42PubMedCrossRefGoogle Scholar
  4. 4.
    Goldie SJ. Chapter 15: public health policy and cost-effectiveness analysis. J Natl Cancer Inst Monogr 2003; 31: 102–10PubMedCrossRefGoogle Scholar
  5. 5.
    Goldie SJ, Goldhaber-Fiebert JD, Garnett G. Chapter 18: public health policy for cervical cancer prevention. The role of decision science, economic evaluation, and mathematical modeling. Vaccine 2006 Aug 31; 24 (S3): 155–63CrossRefGoogle Scholar
  6. 6.
    Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24 (11): 1043–53PubMedCrossRefGoogle Scholar
  7. 7.
    Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003; 106: 896–904PubMedCrossRefGoogle Scholar
  8. 8.
    Yeh JM, Kuntz KM, Ezzati M, et al. Development of an empirically calibrated model of gastric cancer in two high-risk countries. Cancer Epidemiol Biomarkers Prev 2008 May 1; 17 (5): 1179–87PubMedCrossRefGoogle Scholar
  9. 9.
    Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002 May 8; 287 (18): 2372–81PubMedCrossRefGoogle Scholar
  10. 10.
    Urban N, Drescher C, Etzioni R, et al. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials 1997 Jun; 18 (3): 251–70PubMedCrossRefGoogle Scholar
  11. 11.
    Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000 June 15, 2000; 151 (12): 1158–71Google Scholar
  12. 12.
    Law AM, Kelton WD. Simulation modeling and analysis. 3rd ed. Boston (MA): McGraw-Hill, 2000Google Scholar
  13. 13.
    Clarke LD, Plevritis SK, Boer R, et al. A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr 2006; 36: 96–105PubMedCrossRefGoogle Scholar
  14. 14.
    Banks J, editor. Handbook of simulation: principles, methodology, advances, applications, and practice. New York: John Wiley & Sons. Inc., 1998Google Scholar
  15. 15.
    Bruning JL, Kintz BL. Computational handbook of statistics. 4th ed. Boston (MA): Allyn & Bacon, 1997Google Scholar
  16. 16.
    Nelder JA, Mead R. A simplex method for function minimization. Comput J 1965; 7 (4): 308–13CrossRefGoogle Scholar
  17. 17.
    Kirkpatrick S, Gelatt CD, Vecchi MP. Optimization by simulated annealing. Science 1983; 220 (4598): 671–80PubMedCrossRefGoogle Scholar
  18. 18.
    Press WH, Teukolsky SA, Vetterling WT, et al. Numerical recipes in C++. 2nd ed. New York (NY): Cambridge University Press, 2002Google Scholar
  19. 19.
    Wong DF, Leong HW, Liu CL. Simulated annealing for VLSI design. Boston (MA): Kluwer Academic Publishers, 1988CrossRefGoogle Scholar
  20. 20.
    Holland JH. Adaptation in natural and artificial systems. Ann Arbor (MI): University of Michigan Press, 1975Google Scholar
  21. 21.
    Goldberg DE. Genetic algorithms in search, optimization and machine learning. Boston (MA): Kluwer Academic Publishers, 1989Google Scholar
  22. 22.
    Manikas TW, Cain JT. Genetic algorithms vs. simulated annealing: a comparison of approaches for solving the circuit partitioning problem. Pittsburgh (PA): University of Pittsburgh, 1996Google Scholar
  23. 23.
    Ingber L, Rosen B. Genetic algorithms and very fast simulated annealing: a comparison. Math Comput Model 1992; 16 (11): 87–100CrossRefGoogle Scholar
  24. 24.
    Glover F. Tabu search: part I. ORSA J Computing 1989; 1 (3): 190–206CrossRefGoogle Scholar
  25. 25.
    Glover F. Tabu search: part II. ORSA J Computing 1990; 2 (1): 4–32CrossRefGoogle Scholar
  26. 26.
    Kong CY, McMahon PM, Gazelle GS. Calibration of disease simulation models using an engineering approach. Value Health 2009; 12 (4): 521–9PubMedCrossRefGoogle Scholar
  27. 27.
    Baker RD. Use of a mathematical model to evaluate breast cancer screening policy. Health Care Manage Sci 1998 Oct; 1 (2): 103–13CrossRefGoogle Scholar
  28. 28.
    Beckett JR, Kotre CJ, Michaelson JS. Analysis of benefit: risk ratio and mortality reduction for the UK Breast Screening Programme. Br J Radiol 2003 May; 76 (905): 309–20PubMedCrossRefGoogle Scholar
  29. 29.
    Beemsterboer PM, Warmerdam PG, Boer R, et al. Radiation risk of mammography related to benefit in screening programmes: a favourable balance? J Med Screen 1998; 5 (2): 81–7PubMedGoogle Scholar
  30. 30.
    Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant treatment on mortality from breast cancer. N Engl J Med 2005 Oct 27; 353 (17): 1784–92PubMedCrossRefGoogle Scholar
  31. 31.
    Berry DA, Inoue L, Shen Y, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 2006; 36: 30–6PubMedCrossRefGoogle Scholar
  32. 32.
    Blanchard K, Colbert JA, Puri D, et al. Mammographic screening: patterns of use and estimated impact on breast carcinoma survival. Cancer 2004 Aug 1; 101 (3): 495–507PubMedCrossRefGoogle Scholar
  33. 33.
    Boer R, de Koning H, Threlfall A, et al. Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. BMJ 1998 Aug 8; 317 (7155): 376–9PubMedCrossRefGoogle Scholar
  34. 34.
    Boer R, de Koning H, van Oortmarssen G, et al. Stage distribution at first and repeat examinations in breast cancer screening. J Med Screen 1999; 6 (3): 132–8PubMedGoogle Scholar
  35. 35.
    Carter R, Glasziou P, van Oortmarssen G, et al. Cost-effectiveness of mammographic screening in Australia. Aust J Public Health 1993 Mar; 17 (1): 42–50PubMedCrossRefGoogle Scholar
  36. 36.
    Carter KJ, Castro F, Kessler E, et al. A computer model for the study of breast cancer. Comput Biol Med 2003 Jul; 33: 345–60PubMedCrossRefGoogle Scholar
  37. 37.
    Carter KJ, Castro F, Kessler E, et al. Simulation of breast cancer screening: quality assessment of two protocols. J Healthc Qual 2004 Nov-Dec; 26 (6): 31–8PubMedCrossRefGoogle Scholar
  38. 38.
    Castro F, Carter KJ, Kessler E, et al. The relation of breast cancer staging to screening protocol compliance: a computer simulation study. Comput Biol Med 2005 Feb; 35 (2): 91–101PubMedCrossRefGoogle Scholar
  39. 39.
    Chia YL, Salzman P, Plevritis SK, et al. Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration. Stat Methods Med Res 2004 Dec; 13 (6): 507–24PubMedCrossRefGoogle Scholar
  40. 40.
    Cong XJ, Shen Y, Miller AB. Estimation of age-specific sensitivity and sojourn time in breast cancer screening studies. Stat Med 2005 Oct 30; 24 (20): 3123–38PubMedCrossRefGoogle Scholar
  41. 41.
    Connor RJ, Boer R, Prorok PC, et al. Investigation of design and bias issues in case-control studies of cancer screening using microsimulation. Am J Epidemiol 2000 May 15; 151 (10): 991–8PubMedCrossRefGoogle Scholar
  42. 42.
    de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness: policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991 Oct 21; 49: 531–7CrossRefGoogle Scholar
  43. 43.
    de Koning HJ, Boer R, Warmerdam PG, et al. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst 1995 Aug 16; 87 (16): 1217–23PubMedCrossRefGoogle Scholar
  44. 44.
    Eddy DM. Screening for breast cancer. Ann Intern Med 1989; 111 (5): 389–99PubMedGoogle Scholar
  45. 45.
    Feldstein M, Zelen M. Inferring the natural time history of breast cancer: implications for tumor growth rate and early detection. Breast Cancer Res Treat 1984; 4: 3–10PubMedCrossRefGoogle Scholar
  46. 46.
    Fett MJ. Computer modelling of the Swedish two county trial of mammographic screening and trade offs between participation and screening interval. J Med Screen 2001; 8 (1): 39–45PubMedCrossRefGoogle Scholar
  47. 47.
    Fracheboud J, Groenewoud JH, Boer R, et al. Seventy-five years is an appropriate upper age limit for population-based mammography screening. Int J Cancer 2006 Apr 15; 118 (8): 2020–5PubMedCrossRefGoogle Scholar
  48. 48.
    Fryback DG, Stout NK, Rosenberg MA, et al. The Wisconsin breast cancer epidemiology simulation model. J Natl Cancer Inst Monogr 2006; 36: 37–47PubMedCrossRefGoogle Scholar
  49. 49.
    Hanin LG, Miller A, Zorin AV, et al. The University of Rochester model of breast cancer detection and survival. J Natl Cancer Inst Monogr 2006; 36: 66–78PubMedCrossRefGoogle Scholar
  50. 50.
    Hsieh HJ, Chen TH, Chang SH. Assessing chronic disease progression using non-homogeneous exponential regression Markov models: an illustration using a selective breast cancer screening in Taiwan. Stat Med 2002 Nov 30; 21 (22): 3369–82PubMedCrossRefGoogle Scholar
  51. 51.
    Hunter DJ, Drake SM, Shortt SE, et al. Simulation modeling of change to breast cancer detection age eligibility recommendations in Ontario, 2002–2021. Cancer Detect Prev 2004; 28 (6): 453–60PubMedCrossRefGoogle Scholar
  52. 52.
    Jacobi CE, Jonker MA, Nagelkerke NJ, et al. Prevalence of family histories of breast cancer in the general population and the incidence of related seeking of health care [letter]. J Med Genet 2003 Jul; 40 (7): e83CrossRefGoogle Scholar
  53. 53.
    Jacobi CE, Nagelkerke NJ, van Houwelingen JH, et al. Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study. Cancer Epidemiol Biomarkers Prev 2006 Mar; 15 (3): 429–36PubMedCrossRefGoogle Scholar
  54. 54.
    Jansen JT, Zoetelief J. MBS: a model for risk benefit analysis of breast cancer screening. Br J Radiol 1995 Feb; 68 (806): 141–9PubMedCrossRefGoogle Scholar
  55. 55.
    Jansen JT, Zoetelief J. Assessment of lifetime gained as a result of mammographic breast cancer screening using a computer model. Br J Radiol 1997 Jun; 70 (834): 619–28PubMedGoogle Scholar
  56. 56.
    Jansen JT, Zoetelief J. Optimisation of mammographic breast cancer screening using a computer simulation model. Eur J Radiol 1997 Feb; 24 (2): 137–44PubMedCrossRefGoogle Scholar
  57. 57.
    Knox EG. Evaluation of a proposed breast cancer screening regimen. BMJ 1988 Sep 10; 297 (6649): 650–4PubMedCrossRefGoogle Scholar
  58. 58.
    Koscielny S, Tubiana M, Valleron AJ. A simulation model of the natural history of human breast cancer. Br J Cancer 1985 Oct; 52 (4): 515–24PubMedCrossRefGoogle Scholar
  59. 59.
    Lee S, Zelen M. A stochastic model for predicting the mortality of breast cancer. J Natl Cancer Inst Monogr 2006; 36: 79–86PubMedCrossRefGoogle Scholar
  60. 60.
    Mandelblatt JS, Schechter CB, Yabroff KR, et al. Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol 2004 Jul 1; 22 (13): 2554–66PubMedCrossRefGoogle Scholar
  61. 61.
    Mandelblatt J, Schechter CB, Lawrence W, et al. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr 2006; 36: 47–55PubMedCrossRefGoogle Scholar
  62. 62.
    Manton KG, Stallard E. Demographics (1950–1987) of breast cancer in birth cohorts of older women. J Gerontol 1992 Nov; 47 Spec No: 32–42PubMedCrossRefGoogle Scholar
  63. 63.
    Michaelson JS, Halpern E, Kopans DB. Breast cancer: computer simulation method for estimating optimal intervals for screening. Radiology 1999 Aug; 212 (2): 551–60PubMedGoogle Scholar
  64. 64.
    Michaelson JS, Satija S, Moore R, et al. Estimates of breast cancer growth rate and sojourn time from screening database information. J Wom Imag 2003 Feb; 5 (1): 11–9CrossRefGoogle Scholar
  65. 65.
    Michaelson JS, Satija S, Moore R, et al. Estimates of the sizes at which breast cancers become detectable on mammographic and clinical grounds. J Wom Imag 2003 Feb; 5 (1): 3–10CrossRefGoogle Scholar
  66. 66.
    Myles JP, Nixon RM, Duffy SW, et al. Bayesian evaluation of breast cancer screening using data from two studies. Stat Med 2003 May 30; 22 (10): 1661–74PubMedCrossRefGoogle Scholar
  67. 67.
    Okubo I, Glick H, Frumkin H, et al. Cost-effectiveness analysis of mass screening for breast cancer in Japan. Cancer 1991 Apr 15; 67 (8): 2021–9PubMedCrossRefGoogle Scholar
  68. 68.
    Paci E, Boer R, Zappa M, et al. A model-based prediction of the impact on reduction in mortality by a breast cancer screening programme in the city of Florence, Italy. Eur J Cancer 1995; 31A (3): 348–53CrossRefGoogle Scholar
  69. 69.
    Plevritis SK. A mathematical algorithm that computes breast cancer sizes and doubling times detected by screening. Math Biosci 2001 Jun; 171 (2): 155–78PubMedCrossRefGoogle Scholar
  70. 70.
    Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006 May 24; 295 (20): 2374–84PubMedCrossRefGoogle Scholar
  71. 71.
    Plevritis SK, Sigal BM, Salzman P, et al. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr 2006; 36: 86–95PubMedCrossRefGoogle Scholar
  72. 72.
    Plevritis SK, Salzman P, Sigal BM, et al. A natural history model of stage progression applied to breast cancer. Stat Med 2006; 26 (3): 581–95CrossRefGoogle Scholar
  73. 73.
    Shen Y, Huang X. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial. Biometrics 2005 Dec; 61 (4): 992–9PubMedCrossRefGoogle Scholar
  74. 74.
    Shen Y, Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics 2005 Oct; 6 (4): 604–14PubMedCrossRefGoogle Scholar
  75. 75.
    Stout NK, Rosenberg MA, Trentham-Dietz A, et al. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst 2006 Jun 7; 98 (11): 774–82PubMedCrossRefGoogle Scholar
  76. 76.
    Szeto KL, Devlin NJ. The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand. Health Policy 1996 Nov; 38 (2): 101–15PubMedCrossRefGoogle Scholar
  77. 77.
    Tan SYGL, van Oortmarssen GJ, de Koning HJ, et al. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr 2006; 36: 56–65PubMedCrossRefGoogle Scholar
  78. 78.
    Tubiana M, Koscielny S. The natural history of breast cancer: implications for a screening strategy. Int J Radiat Oncol Biol Phys 1990 Nov; 19 (5): 1117–20PubMedCrossRefGoogle Scholar
  79. 79.
    van der Maas PJ, de Koning HJ, van Ineveld BM, et al. The cost-effectiveness of breast cancer screening. Int J Cancer 1989 Jun 15; 43 (6): 1055–60PubMedCrossRefGoogle Scholar
  80. 80.
    van Oortmarssen GJ, Habbema JD, Lubbe JT, et al. A model-based analysis of the HIP project for breast cancer screening. Int J Cancer 1990 Aug 15; 46 (2): 207–13PubMedCrossRefGoogle Scholar
  81. 81.
    van Oortmarssen GJ, Habbema JD, van der Maas PJ, et al. A model for breast cancer screening. Cancer 1990 Oct 1; 66 (7): 1601–12PubMedCrossRefGoogle Scholar
  82. 82.
    Vervoort MM, Draisma G, Fracheboud J, et al. Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality. Br J Cancer 2004 Jul 19; 91 (2): 242–7PubMedGoogle Scholar
  83. 83.
    Berkhof J, de Bruijne MC, Zielinski GD, et al. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. Int J Cancer 2005 Jun 10; 115 (2): 268–75PubMedCrossRefGoogle Scholar
  84. 84.
    Berkhof J, de Bruijne MC, Zielinski GD, et al. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006 Apr 1; 118 (7): 1759–68PubMedCrossRefGoogle Scholar
  85. 85.
    Eddy DM. The frequency of cervical cancer screening: comparison of a mathematical model with empirical data. Cancer 1987 Sep 1; 60 (5): 1117–22PubMedCrossRefGoogle Scholar
  86. 86.
    Eddy DM. Screening for cervical cancer. Ann Intern Med 1990 Aug 1; 113 (3): 214–26PubMedGoogle Scholar
  87. 87.
    Goldie SJ, Weinstein MC, Kuntz KM, et al. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 1999 Jan 19; 130 (2): 97–107PubMedGoogle Scholar
  88. 88.
    Goldie SJ, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001 Jun 27; 285 (24): 3107–15PubMedCrossRefGoogle Scholar
  89. 89.
    Goldie SJ, Kim JJ, Wright TCJ. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004 Apr; 103 (4): 619–31PubMedCrossRefGoogle Scholar
  90. 90.
    Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004 Apr 21; 96 (8): 604–15PubMedCrossRefGoogle Scholar
  91. 91.
    Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005 Nov 17; 353 (20): 2158–68PubMedCrossRefGoogle Scholar
  92. 92.
    Gustafsson L, Adami HO. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer 1989 Jul; 60 (1): 132–41PubMedCrossRefGoogle Scholar
  93. 93.
    Gustafsson L, Adami HO. Cytologic screening for cancer of the uterine cervix in Sweden evaluated by identification and simulation. Br J Cancer 1990 Jun; 61 (6): 903–8PubMedCrossRefGoogle Scholar
  94. 94.
    Gustafsson L, Adami HO. Optimization of cervical cancer screening. Cancer Causes Control 1992 Mar; 3 (2): 125–36PubMedCrossRefGoogle Scholar
  95. 95.
    Gyrd-Hansen D, Holund B, Andersen P. A cost-effectiveness analysis of cervical cancer screening: health policy implications. Health Policy 1995 Oct; 34 (1): 35–51PubMedCrossRefGoogle Scholar
  96. 96.
    Habbema JD, van Oortmarssen GJ, Lubbe JT, et al. Model building on the basis of Dutch cervical cancer screening data. Maturitas 1985 May; 7 (1): 11–20PubMedCrossRefGoogle Scholar
  97. 97.
    Habbema JDF, Lubbe JTN, van Oortmarssen GJ, et al. A simulation approach to cost-effectiveness and cost-benefit calculations of screening for the early detection of disease. Eur J Oper Res 1987 May; 29 (2): 159–66CrossRefGoogle Scholar
  98. 98.
    Helfand M, O’Connor GT, Zimmer-Gembeck M, et al. Effect of the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88) on the incidence of invasive cervical cancer. Med Care 1992 Dec; 30 (12): 1067–82PubMedCrossRefGoogle Scholar
  99. 99.
    Kim JJ, Wright TCJ, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002 May 8; 287 (18): 2382–90PubMedCrossRefGoogle Scholar
  100. 100.
    Kim JJ, Leung GM, Woo PP, et al. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. J Public Health (Oxf) 2004 Jun; 26 (2): 130–7CrossRefGoogle Scholar
  101. 101.
    Knox EG. A simulation system for screening procedures. In: McLachlan G, editor. Future and present indicatives, problems and progress in medical care. 9th rev. Oxford: Nuffield Provincial Hospitals Trust, Oxford University Press, 1973: 17–55Google Scholar
  102. 102.
    Koong SL, Yen AM, Chen TH. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. J Med Screen 2006; 13 Suppl. 1: S44–7Google Scholar
  103. 103.
    Koopmanschap MA, Lubbe KT, van Oortmarssen GJ, et al. Economic aspects of cervical cancer screening. Soc Sci Med 1990; 30 (10): 1081–7PubMedCrossRefGoogle Scholar
  104. 104.
    Kulasingam SL, Myers ER, Lawson HW, et al. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol 2006 Feb; 107 (2 Pt 1): 321–8PubMedCrossRefGoogle Scholar
  105. 105.
    Mandelblatt JS, Lawrence WF, Gaffikin L, et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst 2002 Oct 2; 94 (19): 1469–83PubMedCrossRefGoogle Scholar
  106. 106.
    Mandelblatt J, Lawrence W, Yi B, et al. The balance of harms, benefits, and costs of screening for cervical cancer in older women. Arch Intern Med 2004 Feb 9; 164: 245–7CrossRefGoogle Scholar
  107. 107.
    Matsunaga G, Tsuji I, Sato S, et al. Cost-effective analysis of mass screening for cervical cancer in Japan. J Epidemiol 1997 Sep; 7 (3): 135–41PubMedCrossRefGoogle Scholar
  108. 108.
    Office of Technology Assessment. The costs and effectiveness of screening for cervical cancer in elderly women: background paper, OTA-BP-H-65. Washington, DC: U.S. Congress, 1990Google Scholar
  109. 109.
    Parkin DM. A computer simulation model for the practical planning of cervical cancer screening programmes. Br J Cancer 1985 Apr; 51 (4): 551–68PubMedCrossRefGoogle Scholar
  110. 110.
    Parkin DM, Moss SM. An evaluation of screening policies for cervical cancer in England and Wales using a computer simulation model. J Epidemiol Community Health 1986 Jun; 40 (2): 143–53PubMedCrossRefGoogle Scholar
  111. 111.
    Radensky PW, Mango LJ. Interactive neural-network-assisted screening: an economic assessment. Acta Cytol 1998 Jan-Feb; 42 (1): 246–52PubMedCrossRefGoogle Scholar
  112. 112.
    Sato S, Matunaga G, Tsuji I, et al. Determining the cost-effectiveness of mass screening for cervical cancer using common analytic models. Acta Cytol 1999 Nov-Dec; 43 (6): 1006–14PubMedCrossRefGoogle Scholar
  113. 113.
    Sawaya GF, McConnell KJ, Kulasingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003 Oct 16; 349 (16): 1501–9PubMedCrossRefGoogle Scholar
  114. 114.
    Schechter CB. Cost-effectiveness of rescreening conventionally prepared cervical smears by PAPNET testing. Acta Cytol 1996 Nov-Dec; 40 (6): 1272–82PubMedCrossRefGoogle Scholar
  115. 115.
    Sherlaw-Johnson C, Gallivan S, Jenkins D. Withdrawing low risk women from cervical screening programmes: mathematical modelling study. BMJ 1999 Feb 6; 318 (7180): 356–60PubMedCrossRefGoogle Scholar
  116. 116.
    Sherlaw-Johnson C, Philips Z. An evaluation of liquid-based cytology and human papillomavirus testing within the UK Cervical Cancer Screening Programme. Br J Cancer 2004 Jul 5; 91 (1): 84–91PubMedCrossRefGoogle Scholar
  117. 117.
    Shun-Zhang Y, Miller AB, Sherman GJ. Optimising the age, number of tests, and test interval for cervical screening in Canada. J Epidemiol Community Health 1982 Mar; 36 (1): 1–10PubMedCrossRefGoogle Scholar
  118. 118.
    Sreenivas V, Prabhakar AK, Ravi R, et al. A simulation approach for estimating the loss of woman years due to cervical cancer and probability of developing cervical cancer. Neoplasma 1989; 36 (5): 623–7PubMedGoogle Scholar
  119. 119.
    van Ballegooijen M, van den Akker-van Marle E, Patnick J, et al. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000 Nov; 36 (17): 2177–88PubMedCrossRefGoogle Scholar
  120. 120.
    van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, et al. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002 Feb 6; 94 (3): 193–204PubMedCrossRefGoogle Scholar
  121. 121.
    Clemen RT, Lacke CJ. Analysis of colorectal cancer screening regimens. Health Care Manage Sci 2001 Dec; 4 (4): 257–67CrossRefGoogle Scholar
  122. 122.
    Frazier AL, Colditz GA, Fuchs CS, et al. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000 Oct 18; 284 (15): 1954–61PubMedCrossRefGoogle Scholar
  123. 123.
    Gyrd-Hansen D, Søgaard J, Kronborg O. Analysis of screening data: colorectal cancer. Int J Epidemiol 1997 Dec; 26 (6): 1172–81PubMedCrossRefGoogle Scholar
  124. 124.
    Gyrd-Hansen D, Søgaard J, Kronborg O. Colorectal cancer screening: efficiency and effectiveness. Health Econ 1998 Feb; 7 (1): 9–20PubMedCrossRefGoogle Scholar
  125. 125.
    Haug U, Brenner H. A simulation model for colorectal cancer screening: potential of stool tests with various performance characteristics compared with screening colonoscopy. Cancer Epidemiol Biomarkers Prev 2005 Feb; 14 (2): 422–8PubMedCrossRefGoogle Scholar
  126. 126.
    Khandker RK, Dulski JD, Kilpatrick JB, et al. A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care 2000 Summer; 16 (3): 799–810PubMedCrossRefGoogle Scholar
  127. 127.
    Ladabaum U, Chopra CL, Huang G, et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2001 Nov 6; 135 (9): 769–81PubMedGoogle Scholar
  128. 128.
    Ladabaum U, Scheiman JM, Fendrick AM. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med 2003 May; 114 (7): 546–54PubMedCrossRefGoogle Scholar
  129. 129.
    Lejeune C, Arveux P, Dancourt V, et al. A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer. Eur J Cancer Prev 2003 Feb; 12 (1): 77–84PubMedCrossRefGoogle Scholar
  130. 130.
    Lejeune C, Arveux P, Dancourt V, et al. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. Int J Technol Assess Health Care 2004 Fall; 20 (4): 434–9PubMedCrossRefGoogle Scholar
  131. 131.
    Loeve F, Boer R, van Oortmarssen GJ, et al. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res 1999 Feb; 32 (1): 13–33PubMedCrossRefGoogle Scholar
  132. 132.
    Loeve F, Brown ML, Boer R, et al. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 2000 Apr 5; 92 (7): 557–63PubMedCrossRefGoogle Scholar
  133. 133.
    Loeve F, Boer R, van Oortmarssen GJ, et al. Impact of systematic false-negative test results on the performance of faecal occult blood screening. Eur J Cancer 2001 May; 37 (7): 912–7PubMedCrossRefGoogle Scholar
  134. 134.
    Neilson AR, Whynes DK. Cost-effectiveness of screening for colorectal cancer: a simulation model. IMA J Math Appl Med Biol 1995 Sep-Dec; 12 (3–4): 355–67PubMedCrossRefGoogle Scholar
  135. 135.
    Ness RM, Holmes AM, Klein R, et al. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol 2000 Jul; 95 (7): 1800–11PubMedCrossRefGoogle Scholar
  136. 136.
    Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004 May; 126 (5): 1270–9PubMedCrossRefGoogle Scholar
  137. 137.
    Vijan S, Hwang EW, Hofer TP, et al. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 2001 Dec 1; 111 (8): 593–601PubMedCrossRefGoogle Scholar
  138. 138.
    Wagner JL, Herdman RC, Wadhwa S. Cost effectiveness of colorectal cancer screening in the elderly. Ann Intern Med 1991 Nov 15; 115 (10): 807–17PubMedGoogle Scholar
  139. 139.
    Wagner JL, Tunis S, Brown M, et al. Cost-effectiveness of colorectal cancer screening in average-risk adults. In: Young G, Rosen P, Levin B, editors. Prevention and early detection of colorectal cancer. Philadelphia (PA): Saunders, 1996: 321–56Google Scholar
  140. 140.
    Whynes DK, Neilson AR, Walker AR, et al. Faecal occult blood screening for colorectal cancer: is it cost-effective? Health Econ 1998 Feb; 7 (1): 21–9PubMedCrossRefGoogle Scholar
  141. 141.
    Wong JM, Yen MF, Lai MS, et al. Progression rates of colorectal cancer by Dukes’ stage in a high-risk group: analysis of selective colorectal cancer screening. Cancer J 2004 May-Jun; 10 (3): 160–9PubMedCrossRefGoogle Scholar
  142. 142.
    Yang KC, Liao CS, Chiu YH, et al. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan. J Med Screen 2006; 13 Suppl. 1: S8–13CrossRefGoogle Scholar
  143. 143.
    Garside R, Pitt M, Somerville M, et al. Surveillance of Barrett’s oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 2006 Mar; 10 (8): 1–142PubMedGoogle Scholar
  144. 144.
    Davies R, Crabbe D, Roderick P, et al. A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Manage Sci 2002 Nov; 5 (4): 249–58CrossRefGoogle Scholar
  145. 145.
    Fendrick AM, Chernew ME, Hirth RA, et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999 Jan 25; 159 (2): 142–8PubMedCrossRefGoogle Scholar
  146. 146.
    Roderick P, Davies R, Raftery J, et al. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess 2003; 7 (6): 1–86PubMedGoogle Scholar
  147. 147.
    Roderick P, Davies R, Raftery J, et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen 2003; 10 (3): 148–56PubMedCrossRefGoogle Scholar
  148. 148.
    Das P, Ng AK, Earle CC, et al. Computed tomography screening for lung cancer in Hodgkin’s lymphoma survivors: decision analysis and cost-effectiveness analysis. Ann Oncol 2006 May; 17 (5): 785–93PubMedCrossRefGoogle Scholar
  149. 149.
    Flehinger BJ, Kimmel M. The natural history of lung cancer in a periodically screened population. Biometrics 1987 Mar; 43 (1): 127–44PubMedCrossRefGoogle Scholar
  150. 150.
    Flehinger BJ, Kimmel M, Melamed MR. Natural history of adenocarcinoma-large cell carcinoma of the lung: conclusions from screening programs in New York and Baltimore. J Natl Cancer Inst 1988 May 4; 80 (5): 337–44PubMedCrossRefGoogle Scholar
  151. 151.
    Flehinger BJ, Kimmel M, Polyak T, et al. Screening for lung cancer: the Mayo Lung Project revisited. Cancer 1993 Sep 1; 72 (5): 1573–80PubMedCrossRefGoogle Scholar
  152. 152.
    Gorlova OY, Kimmel M, Henschke C. Modeling of long-term screening for lung carcinoma. Cancer 2001 Sep 15; 92 (6): 1531–40PubMedCrossRefGoogle Scholar
  153. 153.
    Mahadevia PJ, Fleisher LA, Frick KD, et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 2003 Jan 15; 289 (3): 313–22PubMedCrossRefGoogle Scholar
  154. 154.
    Marshall D, Simpson KN, Earle CC, et al. Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort. Lung Cancer 2001 Jun; 32 (3): 227–36PubMedCrossRefGoogle Scholar
  155. 155.
    Yamaguchi N, Tamura Y, Sobue T, et al. Evaluation of cancer prevention strategies by computerized simulation model: an approach to lung cancer. Cancer Causes Control 1991 May; 2 (3): 147–55PubMedCrossRefGoogle Scholar
  156. 156.
    Yamaguchi N, Mizuno S, Akiba S, et al. A 50-year projection of lung cancer deaths among Japanese males and potential impact evaluation of anti-smoking measures and screening using a computerized simulation model. Jpn J Cancer Res 1992 Mar; 83 (3): 251–7PubMedCrossRefGoogle Scholar
  157. 157.
    Yamaguchi N, Tamura Y, Sobue T, et al. Evaluation of cancer prevention strategies by computerized simulation model: methodological issues. Environ Health Perspect 1994 Nov; 102 Suppl. 8: 67–71PubMedCrossRefGoogle Scholar
  158. 158.
    Girgis A, Clarke P, Burton RC, et al. Screening for melanoma by primary health care physicians: a cost-effectiveness analysis. J Med Screen 1996; 3 (1): 47–53PubMedGoogle Scholar
  159. 159.
    Downer MC, Jullien JA, Speight PM. An interim determination of health gain from oral cancer and precancer screening: 2. Developing a model of population screening. Community Dent Health 1997 Dec; 14 (4): 227–32PubMedGoogle Scholar
  160. 160.
    Myers ER, Havrilesky LJ, Kulasingam SL, et al. Genomic tests for ovarian cancer detection and management. Evid Rep Technol Assess (Full Rep) 2006 Oct; (145): 1–100Google Scholar
  161. 161.
    Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol 1991; 44 (4–5): 365–80PubMedCrossRefGoogle Scholar
  162. 162.
    Skates SJ, Pauler DK, Jacobs IJ. Screening based on the risk of cancer calculation from Bayesian hierarchical change point and mixture models of longitudinal markers. J Am Stat Assoc 2001; 96 (454): 429–39CrossRefGoogle Scholar
  163. 163.
    Cowen ME, Chartrand M, Weitzel WF. A Markov model of the natural history of prostate cancer. J Clin Epidemiol 1994 Jan; 47 (1): 3–21PubMedCrossRefGoogle Scholar
  164. 164.
    Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003 Jun 18; 95 (12): 868–78PubMedCrossRefGoogle Scholar
  165. 165.
    Draisma G, De Koning HJ. MISCAN: estimating lead-time and over-detection by simulation. BJU Int 2003 Dec; 92 Suppl. 2: 106–11PubMedCrossRefGoogle Scholar
  166. 166.
    Draisma G, Postma R, Schroder FH, et al. Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer 2006 Nov 15; 119 (10): 2366–71PubMedCrossRefGoogle Scholar
  167. 167.
    Etzioni R, Cha R, Cowen ME. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. J Urol 1999 Sep; 162 (3 Pt 1): 741–8PubMedCrossRefGoogle Scholar
  168. 168.
    Etzioni R, Legler JM, Feuer EJ, et al. Cancer surveillance series: interpreting trends in prostate cancer. Part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999 Jun 16; 91 (12): 1033–9PubMedCrossRefGoogle Scholar
  169. 169.
    Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 Jul 3; 94 (13): 981–90PubMedCrossRefGoogle Scholar
  170. 170.
    Krahn MD, Mahoney JE, Eckman MH, et al. Screening for prostate cancer: a decision analytic view. JAMA 1994 Sep 14; 272 (10): 773–80PubMedCrossRefGoogle Scholar
  171. 171.
    Parker C, Muston D, Melia J, et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006 May 22; 94 (10): 1361–8PubMedCrossRefGoogle Scholar
  172. 172.
    Ross KS, Carter HB, Pearson JD, et al. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000 Sep 20; 284 (11): 1399–405PubMedCrossRefGoogle Scholar
  173. 173.
    Ross KS, Guess HA, Carter HB. Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages. Urology 2005 Nov; 66 (5): 1038–42PubMedCrossRefGoogle Scholar
  174. 174.
    Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med 2006 Aug 30; 25 (16): 2846–66PubMedCrossRefGoogle Scholar
  175. 175.
    Kimmel M, Flehinger BJ. Nonparametric estimation of the size-metastasis relationship in solid cancers. Biometrics 1991 Sep; 47 (3): 987–1004PubMedCrossRefGoogle Scholar
  176. 176.
    Wang PE, Wang TT, Chiu YH, et al. Evolution of multiple disease screening in Keelung: a model for community involvement in health interventions? J Med Screen 2006; 13 Suppl. 1: S54–8CrossRefGoogle Scholar
  177. 177.
    Garrison LP. The ISPOR good practice modeling principles: a sensible approach. Be transparent, be reasonable. Value Health 2003 Jan-Feb; 6 (1): 6–8PubMedCrossRefGoogle Scholar
  178. 178.
    Kim JJ, Kuntz KM, Stout NK, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007 July 15, 2007; 166 (2): 137–50CrossRefGoogle Scholar
  179. 179.
    Goldhaber-Fiebert JD, Stout NK, Ortendahl J, et al. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007; 5 (1): 11 [online]. Available from URL: http://www.pophealthmetrics.com/content/5/1/11 [Accessed 2009 Jul 1]PubMedCrossRefGoogle Scholar
  180. 180.
    Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation. Report of the ISPOR task force on good research practices: modeling studies. Value Health 2003 Jan-Feb; 6 (1): 9–17PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Natasha K. Stout
    • 1
    • 2
    Email author
  • Amy B. Knudsen
    • 3
    • 4
  • Chung Yin Kong
    • 3
    • 4
  • Pamela M. McMahon
    • 3
    • 4
  • G. Scott Gazelle
    • 2
    • 3
    • 4
  1. 1.Department of Ambulatory Care and PreventionHarvard Medical School/Harvard Pilgrim Health CareBostonUSA
  2. 2.Program in Health Decision Science, Department of Health Policy and ManagementHarvard School of Public HealthBostonUSA
  3. 3.Institute for Technology AssessmentMassachusetts General HospitalBostonUSA
  4. 4.Department of RadiologyMassachusetts General HospitalBostonUSA

Personalised recommendations